Clinical trials: B-cell Malignancies
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), B-Cell Non-Hodgkin Lymphomas(NHL)
- Trial name
- NCT03588598
- Testing
- SHC014748M
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Primary Objective: Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic…
- Trial name
- ISAKIDS (NCT03860844)
- Testing
- Isatuximab, Dexamethasone or equivalent, Fludarabine
- Where
- 41 sites in United States, Argentina and 14 more
- Volunteers
- 67 people
- Sponsor
- Sanofi
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).
- Trial name
- CAPITAL (NCT05008055)
- Testing
- Capivasertib
- Where
- 17 sites in United States, Canada and 5 more
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Multiple Myeloma
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
- Trial name
- CARTITUDE-2 (NCT04133636)
- Testing
- JNJ-68284528, Lenalidomide, Daratumumab
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 208 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
This is an open-label, Phase I/Ib trial with a dose escalation phase, followed by a dose extension phase. The objective of the dose escalation phase is to evaluate the pharmacokinetics (PK) and MTD of P1446A-05 in…
- Trial name
- NCT02117336
- Testing
- P1446A-05
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Piramal Enterprises Limited
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
- Trial name
- NCT02004522
- Testing
- Duvelisib, Ofatumumab
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 319 people
- Sponsor
- SecuraBio
CD19-positive, Acute Lymphoblastic Leukemia
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia.
- Trial name
- NCT03798509
- Testing
- Human CD19 targeted T Cells Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The primary purpose of this study is to determine if motexafin gadolinium may be an effective treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT00100711
- Testing
- Motexafin Gadolinium
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Pharmacyclics LLC.
B-cell Lymphoma, Acute Myeloid Leukemia
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies
- Conditions
- B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06820268
- Testing
- XS-04 tablet
- Where
- 4 sites in China
- Volunteers
- 168 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Lymphoma, Acute Lymphocytic Leukemia
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
This is an open-label, dose-escalation Phase 1 study of the investigational agent, ON 013105. In laboratory animal studies, ON 013105 has demonstrated anti-cancer activity.
- Trial name
- NCT01049113
- Testing
- ON 013105
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Traws Pharma, Inc.
Relapsed/Refractory Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
This expanded access program will provide continued access to cerdulatinib to eligible participants who experienced clinical benefit from cerdulatinib in Study 13-601 (NCT01994382) and who otherwise meet the eligibility criteria.
- Trial name
- NCT04757259
- Testing
- cerdulatinib
- Sponsor
- Alexion Pharmaceuticals, Inc.
Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
This is an open-label, randomized controlled, multicenter Phase II clinical study primarily evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigator's choice of BR/R2 regimen in patients with…
- Trial name
- NCT07189065
- Testing
- Rocbrutinib, Bendamustine, Rituximab
- Where
- 41 sites in China
- Volunteers
- 150 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma…
- Trial name
- NCT06943872
- Testing
- Sonrotoclax, Obinutuzumab, Rituximab
- Where
- 195 sites in United States, Argentina and 19 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Chronic Lymphocytic Leukemia
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Since in most cases CLL remains an incurable disease, the goals of therapy are to improve quality of life and to prolong survival.
- Trial name
- PROVIDENCE (NCT06125795)
- Where
- 25 sites in Spain
- Volunteers
- 146 people
- Sponsor
- AbbVie
Diffuse Large Cell B-lymphoma
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.
- Trial name
- NCT06854445
- Testing
- TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection
- Where
- 24 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL.
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
- Trial name
- WaveSpan-008 (NCT07519772)
- Testing
- MK-1045
- Where
- 52 sites in United States, Argentina and 14 more
- Volunteers
- 280 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL.
- Trial name
- NCT06428019
- Testing
- Venetoclax, Acalabrutinib, Obinutuzumab
- Where
- 70 sites in United States, Australia and 7 more
- Volunteers
- 170 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL)
- Trial name
- NCT04830137
- Testing
- NX-2127
- Where
- 16 sites in United States
- Volunteers
- 248 people
- Sponsor
- Nurix Therapeutics, Inc.
Lymphocytic Leukemia, Chronic
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics as well as the preliminary efficacy of venetoclax (GDC-0199; ABT-199) administered in combination with obinutuzumab to participants…
- Trial name
- NCT01685892
- Testing
- Obinutuzumab, Venetoclax
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 82 people
- Sponsor
- Genentech, Inc.
Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL)
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety.
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Trial name
- NCT04824794
- Testing
- GEN3014, Daratumumab
- Where
- 52 sites in United States, Australia and 18 more
- Volunteers
- 130 people
- Sponsor
- Genmab
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.